Cited by 381Alzheimer's disease research and treatmentsProtein purification and stabilityDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths

Open access

Snyder, S.W., Ladror, U.S., Wade, W.S., Wang, G.T., Barrett, L.W., Matayoshi, E.D., Huffaker, H.J., Krafft, G.A., Holzman, T.F.·1994·Biophysical Journal

DOI 10.1016/s0006-3495(94)80591-0PMC PMC1225478

Open this paper in CoChat — free account

Abstract

One of the clinical manifestations of Alzheimer's disease is the deposition of the 39-43 residue amyloid-beta (A beta) peptide in aggregated fibrils in senile plaques. Characterization of the aggregation behavior of A beta is one of the critical issues in understanding the role of A beta in the disease process. Using solution hydrodynamics, A beta was observed to form three types of species in phosphate-buffered saline: insoluble aggregates with sedimentation coefficients of approximately 50,000 S and molecular masses of approximately 10(9) Da, "soluble aggregates" with sedimentation coefficients of approximately 30 S and masses of approximately 10(6) Da, and monomer. When starting from monomer, the aggregation kinetics of A beta 1-40 (A beta 40) and A beta 1-42 (A beta 42), alone and in combination, reveal large differences in the tendency of these peptides to aggregate as a function of pH and other solution conditions. At pH 4.1 and 7.0-7.4, aggregation is significantly slower than at pH 5 and 6. Under all conditions, aggregation of the longer A beta 42 was more rapid than A beta 40. Oxidation of Met-35 to the sulfoxide in A beta 40 enhances the aggregation rate over that of the nonoxidized peptide. Aggregation was found to be dependent upon temperature and to be strongly dependent on peptide concentration and ionic strength, indicating that aggregation is driven by a hydrophobic effect. When A beta 40 and A beta 42 are mixed together, A beta 40 retards the aggregation of A beta 42 in a concentration-dependent manner. Shorter fragments have a decreasing ability to interfere with A beta 42 aggregation. Conversely, the rate of aggregation of A beta 40 can be significantly enhanced by seeding slow aggregating solutions with preformed aggregates of A beta 42. Taken together, the inhibition of A beta 42 aggregation by A beta 40, the seeding of A beta 40 aggregation by A beta 42 aggregates, and the chemical oxidation of A beta 40 suggest that the relative abundance and rates of production of different-length A beta and its exposure to radical damage may be factors in the accumulation of A beta in plaques in vivo.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0006-3495(94)80591-0

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Amyloid Deposits and Amyloidosis
Glenner, G. G. (1980) · New England Journal of Medicine · doi:10.1056/nejm198006053022305 · Cited by 1,780
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
An Increased Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βApp 717 ) Mutants
Suzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T. E., & Younkin, S. G. (1994) · Science · doi:10.1126/science.8191290 · Cited by 1,471

Show all 55 references

Research works printed but not linked: 4

Gorevic, P. D., P. C. Munoz, T. T. Casey, C. R. Diraimondo, W. J. Stone, F. C. Prelli, M K Rodrigues, K D. Poulk, and B. Franikone. 1986. Ten to fourt residue pepqides of Alzheimer's disease protein are sufficient for amyloid fibril formaton and its characteristic x-ray dffraction pattern. Proc. Natl Acad Sci USA. 83:7908-7912.
Holzman, T. F., and S. W. Snyder. 1994. Applicatons of analytical ultra- centrugation i sucture-bsed drug design. In Modern Analytical Ul- tracentifugation: Acquisition and Interpretation of Data for Biological and Synthetic Polymer Systems. T. M. Schuster, T. M. Laue, editors. Boston, Birkhauser Division, Springer-Verlag.
Kirschner, D. A, C. R. Abraham, and D. J. Selkoe. 1986. X-ray diffractio from intraneuronal paired helical filaments and extraneuronal amyloid fibminAlzheimer disease indicates cross-beta conformation. Proc. NatiL Acad ScL U.S.A 86:503-507.
Krafft, G. A. 1993. Perspectives on amyloid and Alzheimer's disease: a critical review. Annu. Rep. Mled Chem 28:49-58.

Sorted by citations

Items 101–200 of 380

Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family
Cam (2006) · Molecular Neurodegeneration · doi:10.1186/1750-1326-1-8 · Cited by 106
Preferential accumulation of Aβ(1−42) on gel phase domains of lipid bilayers: An AFM and fluorescence study
Choucair, A., Chakrapani, M., Chakravarthy, B., Katsaras, J., & Johnston, L. J. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.09.005 · Cited by 105
Ligand-Dependent Inhibition and Reversal of Tau Filament Formation
Chirita, C. N., Necula, M., & Kuret, J. (2004) · Biochemistry · doi:10.1021/bi036094h · Cited by 104
Alzheimer's amyloid β interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids
Koudinov, A. R., Berezov, T. T., Kumar, A. R., & Koudinova, N. V. (1998) · Clinica Chimica Acta · doi:10.1016/s0009-8981(97)00207-6 · Cited by 102
Transient dynamics of Aβ contribute to toxicity in Alzheimer’s disease
Hubin, E., van Nuland, N. A. J., Broersen, K., & Pauwels, K. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1634-z · Cited by 102
Aβ40 Protects Non-toxic Aβ42 Monomer from Aggregation
Yan, Y., & Wang, C. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.04.014 · Cited by 99
Neuroprotective approaches in experimental models of β-Amyloid neurotoxicity: Relevance to Alzheimer's disease
Harkany, T., Hortobágyi, T., Sasvári, M., Kónya, C., Penke, B., Luiten, P. G. M., & Nyakas, C. J. (1999) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(99)00058-5 · Cited by 97
Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques
Kumar‐Singh, S. (2008) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00380.x · Cited by 101
Residue-Specific pKaMeasurements of the β-Peptide and Mechanism of pH-Induced Amyloid Formation
Ma, K., Clancy, E. L., Zhang, Y., Ray, D. G., Wollenberg, K., & Zagorski, M. G. (1999) · Journal of the American Chemical Society · doi:10.1021/ja990864o · Cited by 94
Profile of Changes in Lipid Bilayer Structure Caused by β-Amyloid Peptide
Kremer, J. J., Sklansky, D. J., & Murphy, R. M. (2001) · Biochemistry · doi:10.1021/bi010417x · Cited by 93
Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease
Faivre, É., Coelho, J. E., Zornbach, K., Malik, E. M., Baqi, Y., Schneider, M., Cellai, L., Carvalho, K., Sebda, S., Figeac, M., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00235 · Cited by 93
pH-Dependent Amyloid and Protofibril Formation by the ABri Peptide of Familial British Dementia
Srinivasan, R., Jones, E. M., Liu, K., Ghiso, J. A., Marchant, R. E., & Zagorski, M. G. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.09.001 · Cited by 89
Towards an understanding of amyloidogenesis
Kelly, J. W. (2002) · Nature Structural Biology · doi:10.1038/nsb0502-323 · Cited by 89
Molecular Interactions of Dendrimers with Amyloid Peptides: pH Dependence
Klajnert‐Maculewicz, B., Cladera, J., & Bryszewska, M. J. (2006) · Biomacromolecules · doi:10.1021/bm060229s · Cited by 86
Combined Effects of Agitation, Macromolecular Crowding, and Interfaces on Amyloidogenesis
Lee, C. F., Bird, S. H., Shaw, M. K., Jean, L., & Vaux, D. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.400580 · Cited by 87
Cerebral Amyloid Angiopathy
(2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00006-0 · Cited by 84
Solution Structure Model of Residues 1−28 of the Amyloid β-Peptide When Bound to Micelles
Marcinowski, K. J., Shao, H., Clancy, E. L., & Zagorski, M. G. (1998) · Journal of the American Chemical Society · doi:10.1021/ja9738687 · Cited by 81
Differential modulation of plasma β-amyloid by insulin in patients with Alzheimer disease
Kulstad, J. J., Green, P. S., Cook, D. G., Watson, G. S., Reger, M. A., Baker, L. D., Plymate, S. R., Asthana, S., Rhoads, K., Mehta, P. D., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000216274.58185.09 · Cited by 84
Fine mapping of the -T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer's disease pedigrees
Ertekin-Taner, N. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg343 · Cited by 80
Rapid aggregation and assembly in aqueous solution of Aβ (25–35) peptide
Millucci, L., Raggiaschi, R., Franceschini, D., Terstappen, G. C., & Santucci, A. (2009) · Journal of Biosciences · doi:10.1007/s12038-009-0033-3 · Cited by 79
Docosahexaenoic acid disrupts in vitro amyloid β1‐40 fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer’s disease model rats
Hashimoto, M., Shahdat, H. M., Yamashita, S., Katakura, M., Tanabe, Y., Fujiwara, H., Gamoh, S., Miyazawa, T., Arai, H., Shimada, T., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05731.x · Cited by 80
l-theanine protects the APP (Swedish mutation) transgenic SH-SY5Y cell against glutamate-induced excitotoxicity via inhibition of the NMDA receptor pathway
Di, X., Yan, J., Zhao, Y., Zhang, J., Shi, Z., Chang, Y. Z., & Zhao, B. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.04.019 · Cited by 78
Activation of PARP by Oxidative Stress Induced by β-Amyloid: Implications for Alzheimer’s Disease
Abeti, R., & Duchen, M. R. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0895-x · Cited by 80
Influence of gold nanoparticle surface chemistry and diameter upon Alzheimer’s disease amyloid-β protein aggregation
Moore, K. A., Pate, K. M., Soto-Ortega, D. D., Lohse, S. E., van der Munnik, N. P., Lim, M., Jackson, K. S., Lyles, V. D., Jones, L., Glassgow, N., et al. (2017) · Journal of Biological Engineering · doi:10.1186/s13036-017-0047-6 · Cited by 78
Mass spectrometry‐based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids
Korecka, M., & Shaw, L. M. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15465 · Cited by 82
Recovery and purification of highly aggregation-prone disulfide-containing peptides: Application to islet amyloid polypeptide
Abedini, A., Singh, G., & Raleigh, D. P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.11.029 · Cited by 76
Methods for Analysis of Amyloid-β Aggregates
Bruggink, K. A., Müller, M., Kuiperij, H. B., & Verbeek, M. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111421 · Cited by 76
A comparative analysis of the aggregation behavior of amyloid‐β peptide variants
Vandersteen, A., Hubin, E., Sarroukh, R., Baets, G. D., Schymkowitz, J. W. H., Rousseau, F., Subramaniam, V., Raussens, V., Wenschuh, H., Wildemann, D., et al. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.10.022 · Cited by 76
Effect of Poly(propylene imine) Glycodendrimers on β-Amyloid Aggregation in Vitro and in APP/PS1 Transgenic Mice, as a Model of Brain Amyloid Deposition and Alzheimer’s Disease
Klementieva, O. L., Aso, E., Filippini, D., Benseny‐Cases, N., Carmona, M., Juvés, S., Appelhans, D., Cladera, J., & Ferrer, I. (2013) · Biomacromolecules · doi:10.1021/bm400948z · Cited by 74
Melatonin: A potential nighttime guardian against Alzheimer’s
Zhang, Z., Xue, P., Bendlin, B. B., Zetterberg, H., Felice, F. G. D., Tan, X. W., & Benedict, C. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02691-6 · Cited by 76
A Strand-Loop-Strand Structure Is a Possible Intermediate in Fibril Elongation: Long Time Simulations of Amyloid-β Peptide (10−35)
Han, W., & Wu, Y. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051699h · Cited by 73
Metal Loading Capacity of Aβ N-Terminus: a Combined Potentiometric and Spectroscopic Study of Zinc(II) Complexes with Aβ(1−16), Its Short or Mutated Peptide Fragments and Its Polyethylene Glycol−ylated Analogue
Damante, C. A., Ösz, K., Nagy, Z., Pappalardo, G., Grasso, G., Impellizzeri, G., Rizzarelli, E., & Sóvágó, I. (2009) · Inorganic Chemistry · doi:10.1021/ic9012334 · Cited by 70
The coexistence of an equal amount of Alzheimer's amyloid‐β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathway
Chang, Y., & Chen, Y. (2014) · FEBS Journal · doi:10.1111/febs.12813 · Cited by 68
Enrichment of Amyloidogenesis at an Air-Water Interface
Jean, L., Lee, C. F., & Vaux, D. J. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.01.041 · Cited by 70
Pentapeptide Amides Interfere with the Aggregation of β-Amyloid Peptide of Alzheimer's Disease
Hetényi, C., Szabó, Z., Klement, É., Datki, Z., Körtvélyesi, T., Zarándi, M., & Penke, B. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6745 · Cited by 67
Signaling effect of amyloid-β42 on the processing of AβPP
Tabaton, M., Zhu, X., Perry, G. L., Smith, M. A., & Giliberto, L. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.002 · Cited by 74
Amyloid beta oligomers induce neuronal elasticity changes in age-dependent manner: a force spectroscopy study on living hippocampal neurons
Ungureanu, A.-A., Benilova, I., Krylychkina, O., Braeken, D., Strooper, B. D., Haesendonck, C. V., Dotti, C. G., & Bartic, C. (2016) · Scientific Reports · doi:10.1038/srep25841 · Cited by 64
Mitigating Alzheimer’s Disease with Natural Polyphenols: A Review
Gaudreault, R., & Mousseau, N. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190315093520 · Cited by 65
Spontaneous in Vitro Formation of Supramolecular β-Amyloid Structures, “βamy Balls”, by β-Amyloid 1−40 Peptide
Westlind‐Danielsson, A., & Arnerup, G. (2001) · Biochemistry · doi:10.1021/bi010375c · Cited by 63
Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease
Rajani, R. M., Ellingford, R., Hellmuth, M., Harris, S. S., Taso, O. S., Graykowski, D., Lam, F. K. W., Arber, C., Fertan, E., Danial, J. S. H., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002727 · Cited by 62
“The increased A β 42:40 ratio in oligodendrocytes could contribute to the high proportion of soluble aggregates [28,42,43]; it is also worth noting that the relationship between A β monomer concentration and aggregate concentration is nonlinear, so small changes in monomer can result in larger…”
Background
Interaction between synthetic amyloid‐β‐peptide (1–40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry
Skribanek, Z., Baláspiri, L., & Mák, M. (2001) · Journal of Mass Spectrometry · doi:10.1002/jms.243 · Cited by 62
β-Amyloid-induced toxicity in rat hippocampal cells: In vitro evidence for the involvement of free radicals
Manelli, A. M., & Puttfarcken, P. S. (1995) · Brain Research Bulletin · doi:10.1016/0361-9230(95)02034-x · Cited by 62
Oligomerization of β-amyloid of the Alzheimer’s and the Dutch-cerebral-haemorrhage types
SIAN, A. K., Frears, E. R., El‐Agnaf, O. M. A., PATEL, B. P., Manca, M. F., Siligardi, G., Hussain, R., & Austen, B. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3490299 · Cited by 61
In vitro fibrillogenesis of the amyloid β1–42 peptide: cholesterol potentiation and aspirin inhibition
Harris, J. R. (2002) · Micron · doi:10.1016/s0968-4328(02)00029-x · Cited by 59
Clusterin contributes to early stage of Alzheimer's disease pathogenesis
Oh, S., Kim, M. S., Park, S., Son, H., Kim, S., Kim, M., Jo, D., Tak, E., & Lee, J. (2018) · Brain Pathology · doi:10.1111/bpa.12660 · Cited by 59
Assembly and Kinetic Folding Pathways of a Tetrameric β-Sheet Complex: Molecular Dynamics Simulations on Simplified Off-Lattice Protein Models
Jang, H., Hall, C. K., & Zhou, Y. (2004) · Biophysical Journal · doi:10.1016/s0006-3495(04)74081-3 · Cited by 57
Change and stabilization of the amyloid-β(1–40) secondary structure by fluorocompounds
Vieira, E. P., Hermel, H., & Möhwald, H. (2003) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/s1570-9639(02)00461-2 · Cited by 56
Exploration of the mechanism for LPFFD inhibiting the formation of β-sheet conformation of Aβ(1–42) in water
Cao, Y., Zhu, X., Li, J., & Shi, R. (2010) · Journal of Molecular Modeling · doi:10.1007/s00894-009-0594-y · Cited by 55
Activation of complement and contact system in Alzheimer's disease
Bergamaschini, L. C., Donarini, C., Gobbo, G. F. D., Parnetti, L., & Gallai, V. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00311-6 · Cited by 54
The Effects of Long-Term Treatment with Metrifonate, a Cholinesterase Inhibitor, on Cholinergic Activity, Amyloid Pathology, and Cognitive Function in APP and PS1 Doubly Transgenic Mice
Liu, L., Ikonen, S., Heikkinen, T., Tapiola, T., Groen, T. V., & Tanila, H. (2002) · Experimental Neurology · doi:10.1006/exnr.2001.7819 · Cited by 51
Relationship Between Multifunctional Protein "Clusterin" and Alzheimer Disease
Choi-Miura, N.-H., & Oda, T. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00106-6 · Cited by 54
Mapping of Possible Binding Sequences of Two Beta-Sheet Breaker Peptides on Beta Amyloid Peptide of Alzheimer's Disease
Hetényi, C., Körtvélyesi, T., & Penke, B. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00424-2 · Cited by 52
The use of mass spectrometry to study amyloid‐β peptides
Grasso, G. (2010) · Mass Spectrometry Reviews · doi:10.1002/mas.20281 · Cited by 51
Cross‐seeding between Aβ40 and Aβ42 in Alzheimer's disease
Tran, J., Chang, D., Hsu, F., Wang, H., & Guo, Z. (2016) · FEBS Letters · doi:10.1002/1873-3468.12526 · Cited by 53
The amyloidogenicity of gelsolin is controlled by proteolysisand pH
Ratnaswamy, G., Koepf, E. K., Bekele, H., Yin, H. L., & Kelly, J. W. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80075-1 · Cited by 51
Alzheimer's disease: molecular concepts and therapeutic targets
Fassbender, K. C., Masters, C. L., & Beyreuther, K. T. (2001) · Die Naturwissenschaften · doi:10.1007/s001140100237 · Cited by 51
Intercommunication between metal ions and amyloidogenic peptides or proteins in protein misfolding disorders
Suh, J., Kim, M., Yoo, J., Han, J., Paulina, C., & Lim, M. H. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214978 · Cited by 49
Diseases of protein aggregation and the hunt for potential pharmacological agents
Wang, S. S. ‐., Wu, J. W., Yamamoto, S., & Liu, H. (2007) · Biotechnology Journal · doi:10.1002/biot.200700065 · Cited by 49
Cu II Binding to Various Forms of Amyloid‐β Peptides: Are They Friends or Foes?
Borghesani, V., Aliès, B., & Hureau, C. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201700776 · Cited by 50
Modulation of Fibrillogenesis of Amyloid β(1−40) Peptide with Cationic Gemini Surfactant
Cao, M., Han, Y., Wang, J., & Wang, Y. (2007) · The Journal of Physical Chemistry B · doi:10.1021/jp075271b · Cited by 49
Amyloid peptide Aβ40 inhibits aggregation of Aβ42: Evidence from molecular dynamics simulations
Man, V. H., & Li, M. S. (2012) · The Journal of Chemical Physics · doi:10.1063/1.4730410 · Cited by 47
Surface plasmon resonance biosensors for simultaneous monitoring of amyloid-beta oligomers and fibrils and screening of select modulators
Yi, X., Feng, C., Hu, S., Li, H., & Wang, J. (2015) · The Analyst · doi:10.1039/c5an01864a · Cited by 52
Copper‐dependent inhibition of cytochrome c oxidase by Aβ1−42 requires reduced methionine at residue 35 of the Aβ peptide
Crouch, P. J., Barnham, K. J., Duce, J. A., Blake, R. E., Masters, C. L., & Trounce, I. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04050.x · Cited by 46
Tautomeric Effect of Histidine on the Monomeric Structure of Amyloid β-Peptide(1–40)
Shi, H., Kang, B., & Lee, J. Y. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b08685 · Cited by 47
Reversible Inactivation of Superoxide‐Sensitive Aconitase in Aβ1‐42‐Treated Neuronal Cell Lines
Longo, V. D., Viola, K. L., Klein, W. L., & Finch, C. E. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751977.x · Cited by 46
An FT-IR Study of the β-Amyloid Conformation: Standardization of Aggregation Grade
Szabó, Z., Klement, É., Jost, K., Zarándi, M., Soós, K., & Penke, B. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1667 · Cited by 45
Protein clearance strategies for disease intervention
Hommen, F., Bilican, S., & Vílchez, D. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02431-y · Cited by 48
Tautomeric Effect of Histidine on the Monomeric Structure of Amyloid β-Peptide(1–42)
Shi, H., & Lee, J. Y. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00375 · Cited by 44
Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis
Almeida, Z. L., Vaz, D. C., & Brito, R. M. M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04543-4 · Cited by 49
Chemical Biology, Molecular Mechanism and Clinical Perspective of γ - Secretase Modulators in Alzheimers Disease
Bulic, B., Neß, J., Hahn, S., Rennhack, A., Jumpertz, T., & Weggen, S. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376352 · Cited by 43
Understanding co-polymerization in amyloid formation by direct observation of mixed oligomers
Young, L. M., Tu, L., Raleigh, D. P., Ashcroft, A. E., & Radford, S. E. (2017) · Chemical Science · doi:10.1039/c7sc00620a · Cited by 41
Picalm reduction exacerbates tau pathology in a murine tauopathy model
Ando, K., Decker, R. D., Vergara, C., Yilmaz, Z., Mansour, S., Suain, V., Sleegers, K., de Fisenne, M.-A., Houben, S., Potier, M., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02125-x · Cited by 46
Micelle Formation by a Fragment of Human Islet Amyloid Polypeptide
Rhoades, E. R., & Gafni, A. (2003) · Biophysical Journal · doi:10.1016/s0006-3495(03)70068-x · Cited by 41
Nanoprobing of the Effect of Cu2+ Cations on Misfolding, Interaction and Aggregation of Amyloid β Peptide
Lv, Z., Condron, M. M., Teplow, D. B., & Lyubchenko, Y. L. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9416-6 · Cited by 40
Human Alzheimer’s disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology
Rothman, S. M., Tanis, K. Q., Gandhi, P., Malkov, V. A., Marcus, J., Pearson, M. S., Stevens, R. C., Gilliland, J., Ware, C. M., Mahadomrongkul, V., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1265-7 · Cited by 41
Effect of Taiwan Mutation (D7H) on Structures of Amyloid-β Peptides: Replica Exchange Molecular Dynamics Study
Truong, P. M., Man, V. H., Nguyen, P. H., Hu, C., & Li, M. S. (2014) · The Journal of Physical Chemistry B · doi:10.1021/jp503652s · Cited by 39
Amyloid β-peptides 1–40 and 1–42 form oligomers with mixed β-sheets
Baldassarre, M., Baronio, C. M., Morozova‐Roche, L. A., & Barth, A. (2017) · Chemical Science · doi:10.1039/c7sc01743j · Cited by 39
Hereditary and Sporadic Forms of Aβ-Cerebrovascular Amyloidosis and Relevant Transgenic Mouse Models
Kumar‐Singh, S. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10041872 · Cited by 40
Alzheimer's β-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner
Bergamaschini, L. C., Canziani, S., Bottasso, B., Cugno, M., Braidotti, P., & Agostoni, A. (1999) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1999.00835.x · Cited by 39
Study of the non‐covalent interaction between amyloid‐β‐peptide and melatonin using electrospray ionization mass spectrometry
Bazoti, F. N., Tsarbopoulos, A., Markides, K. E., & Bergquist, J. (2005) · Journal of Mass Spectrometry · doi:10.1002/jms.738 · Cited by 38
Duration and Specificity of Humoral Immune Responses in Mice Vaccinated with the Alzheimer's Disease-Associated β -Amyloid 1-42 Peptide
Dickey, C. A., Morgan, D., Kudchodkar, S. B., Weiner, D. B., Bai, Y., Cao, C., Gordon, M. N., & Ugen, K. E. (2001) · DNA and Cell Biology · doi:10.1089/10445490152717587 · Cited by 38
Molecular mechanism and therapeutic strategy of bile acids in Alzheimer’s disease from the emerging perspective of the microbiota–gut–brain axis
Wu, M., Cheng, Y., Zhang, R., Han, W., Jiang, H., Bi, C., Zhang, Z., Ye, M., Lin, X., & Liu, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117228 · Cited by 40
Simulations of monomeric amyloid β-peptide (1–40) with varying solution conditions and oxidation state of Met35: Implications for aggregation
Brown, A. M., Lemkul, J. A., Schaum, N., & Bevan, D. R. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.01.002 · Cited by 39
Cajaninstilbene Acid Ameliorates Cognitive Impairment Induced by Intrahippocampal Injection of Amyloid-β1–42 Oligomers
Wang, L.-S., Xue, T., Liu, X., Zhou, Y., Zhang, M.-D., Liao, Y., Pan, R., & Chang, Q. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01084 · Cited by 38
Oxidative and hydrolytic properties of β‐amyloid
Brzyska, M., Bacia, A., & Elbaum, D. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02248.x · Cited by 38
Alzheimer's amyloid-beta peptide inhibits sodium/calcium exchange measured in rat and human brain plasma membrane vesicles
Wu, A., D’Errico, C., Hatem, L., & Colvin, R. A. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00053-5 · Cited by 38
Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1–42 in CSF for the Diagnosis of Alzheimer’s Disease
Pottiez, G., Yang, L., Stewart, T., Song, N., Aro, P., Galasko, D. R., Quinn, J. F., Peskind, E. R., Shi, M., & Zhang, J. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00829 · Cited by 37
Amyloid-β peptide (1–42) aggregation induced by copper ions under acidic conditions
Bin, Y., Li, X., He, Y., Chen, S., & Xiang, J. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt044 · Cited by 36
Performance Characteristics of Plasma Amyloid-β 40 and 42 Assays
Okereke, O. I., Xia, W., Irizarry, M. C., Sun, X., Qiu, W. Q., Fagan, A. M., Mehta, P. D., Hyman, B. T., Selkoe, D. J., & Grodstein, F. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0948 · Cited by 38
Eight-residue Aβ peptides inhibit the aggregation and enzymatic activity of Aβ42
Matsunaga, Y., Fujii, A., Awasthi, A., Yokotani, J., Takakura, T., & Yamada, T. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.03.013 · Cited by 38
The region 1–11 of Alzheimer amyloid-β is critical for activation of contact-kinin system
Bergamaschini, L. C. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00174-3 · Cited by 38
Insights into the Interaction Mechanism of Ligands with Aβ42 Based on Molecular Dynamics Simulations and Mechanics: Implications of Role of Common Binding Site in Drug Design for Alzheimer's Disease
Kundaikar, H., & Degani, M. S. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12555 · Cited by 35
Dynamic Imaging by Fluorescence Correlation Spectroscopy Identifies Diverse Populations of Polyglutamine Oligomers Formed in Vivo
Beam, M., Silva, M. C., & Morimoto, R. I. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.362764 · Cited by 32
MALDI, AP/MALDI and ESI techniques for the MS detection of amyloid β-peptides
Grasso, G., Mineo, P. G., Rizzarelli, E., & Spoto, G. (2009) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2009.02.008 · Cited by 33
Golgi-Associated plant Pathogenesis Related protein 1 (GAPR-1) forms amyloid-like fibrils by interaction with acidic phospholipids and inhibits Aβ aggregation
Olrichs, N. K., Mahalka, A. K., Kaloyanova, D. V., Kinnunen, P. K. J., & Helms, J. B. (2014) · Amyloid · doi:10.3109/13506129.2014.882304 · Cited by 32
Mechanical and thermodynamic properties of Aβ 42 , Aβ 40 , and α-synuclein fibrils: a coarse-grained method to complement experimental studies
Poma, A. B., Guzman, H. V., Li, M. S., & Theodorakis, P. E. (2019) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.10.51 · Cited by 32
Surprising toxicity and assembly behaviour of amyloid β-protein oxidized to sulfone
Maiti, P., Piacentini, R., Ripoli, C., Grassi, C., & Bitan, G. (2010) · Biochemical Journal · doi:10.1042/bj20101391 · Cited by 31
Structural analysis of amyloid β peptide fragment (25–35) in different microenvironments
Shanmugam, G., & Rajadas, J. (2004) · Biopolymers · doi:10.1002/bip.20131 · Cited by 31
The influence of the central region containing residues 19−25 on the aggregation properties and secondary structure of Alzheimer's β‐amyloid peptide
El‐Agnaf, O. M. A., Guthrie, D. J. S., Walsh, D. M., & Irvine, G. B. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2560560.x · Cited by 31
Methionine oxidation reduces lag-times for amyloid-β(1–40) fiber formation but generates highly fragmented fibers
Gu, M., & Viles, J. H. (2016) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2016.04.009 · Cited by 30

Authors: Snyder, S. W., Ladror, U. S., Wade, W. S., Wang, G. T., Barrett, L. W., Matayoshi, E. D., Huffaker, H. J., Krafft, G. A., & Holzman, T. F.
Affiliations: Abbott (United Kingdom) (GB)
Corresponding author: Holzman, T.F.
ORCID: Snyder, S.W.
Barrett, L.W.
Venue: Biophysical Journal
Publisher: Elsevier BV
Published: 1994-09
Volume: 67
Issue: 3
Pages: 1216-1228
ISSN: 0006-3495 (ISSN-L)
DOI: 10.1016/s0006-3495(94)80591-0
PMC: PMC1225478
OpenAlex: W2024559246
Cited by: 381
References: 55
Citations by year: 2026: 4 · 2025: 2 · 2024: 17 · 2023: 5 · 2022: 9 · 2021: 20 · 2020: 8 · 2019: 12 · 2018: 9 · 2017: 18 · 2016: 13 · 2015: 9 · 2014: 10 · 2013: 18 · 2012: 17
FWCI: 7.03
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 6893 d)
Locations: Biophysical Journal (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Abbott Laboratories
National Institutes of Health (7p01ag010481-05)
National Institute on Aging (AG10481)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: amyloid-beta aggregation, Alzheimer's disease, Aβ40, amyloid-beta 42, peptide length, aggregation kinetics, hydrophobic effect, seeding, aggregation inhibition, pH dependence, ionic strength, amyloid plaques
MeSH terms: Alzheimer Disease, Amino Acid Sequence, Biophysics, Humans, Kinetics, Microscopy, Electron, Molecular Sequence Data, Polymers, Protein Conformation, Solutions, Amyloid beta-Peptides, Neurofibrillary Tangles, Macromolecular Substances, Biophysical Phenomena, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks